Regulatory and scientific aspects of the proposed replacement chlorofluorocarbons (CFCs) in medicinal products are discussed. Preclinical toxicity studies as well as clinical safety and effectiveness studies are needed for an adequate assessment of the new propellants used in drug products. © 1991, Mary Ann Liebert, Inc. All rights reserved.